RecruitingNCT06409832

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)


Sponsor

University of Florence

Enrollment

100 participants

Start Date

Mar 26, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
  • At least 4 monthly migraine days;
  • Good compliance to study procedures;
  • Availability of headache diary at least of the preceding months before enrollment.

Exclusion Criteria5

  • Subjects with contraindications for use of gepants;
  • Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
  • medical comorbidities that could interfere with study results;
  • Pregnancy and breastfeeding.
  • Changes in preventive treatments in the month before the first administration of rimegepant

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRimegepant 75 mg

Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention


Locations(2)

SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi

Florence, Italy

IRCCS National Neurological Institute "C. Mondino" Foundation

Pavia, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06409832


Related Trials